Key Takeaways
- • American Industrial Partners (AIP) has agreed to acquire Avanos Medical in an all-cash take-private transaction valued at approximately $1.27 billion, with closing expected in the second half of 2026.
- • Avanos shareholders will receive $25 per share in cash, representing a 72.1% premium to the last closing price before announcement and an 82.8% premium over the 30-day volume-weighted average share price, driving a 68% premarket rally in the stock.
- • AIP's acquisition thesis centers on Coolief, Avanos' lead product utilizing minimally invasive radiofrequency technology for non-opioid chronic pain management, positioning the company within the high-growth pain management segment competing against larger medtech players including Stryker, Medtronic, and Boston Scientific.
- • The transaction is not subject to a financing condition and requires customary approvals including Hart-Scott-Rodino antitrust clearance, regulatory consents, and Avanos stockholder approval before Avanos delists from the NYSE.
- • AIP's investment reflects the firm's strategic focus on acquiring and scaling healthcare platforms with differentiated product portfolios, with Avanos' clinical nutrition solutions (enteral feeding systems) providing additional platform diversification.
Summary
American Industrial Partners has entered into a definitive agreement to acquire Avanos Medical in an all-cash transaction valuing the company at approximately $1.27 billion. The transaction, announced on April 15, 2026, immediately triggered significant market reaction, with Avanos shares rallying approximately 68% in premarket trading following the announcement.
Under the agreement, Avanos shareholders will receive $25 per share in cash. This purchase price represents a 72.1% premium over Avanos' closing stock price on the last trading day before the announcement and an 82.8% premium over the company's 30-day volume-weighted average share price. Avanos Medical's Board of Directors unanimously approved the transaction.
Alpharetta, Georgia-based Avanos Medical specializes in medical devices targeting chronic pain management without opioids, alongside clinical nutrition solutions including enteral feeding systems for patients unable to eat independently. AIP's investment thesis centers on Coolief, the company's flagship product that employs minimally invasive radiofrequency technology to interrupt pain signals by targeting specific nerves. This positioning within the non-opioid pain management segment reflects the broader healthcare industry shift away from opioid-based therapies. Avanos operates within a competitive landscape dominated by established medtech players such as Stryker, Medtronic, and Boston Scientific, which offer competing ablation-based solutions as part of their broader device portfolios.
The transaction is expected to close in the second half of 2026, subject to customary approvals and conditions including Avanos stockholder approval, expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, and other regulatory consents. Notably, the deal is not subject to a financing condition. Following closing, Avanos will become a private company and will delist from the New York Stock Exchange.
JP Morgan Securities served as lead financial adviser to Avanos, with UBS Investment Bank also acting as financial adviser. Alston & Bird provided legal counsel to Avanos, while Joele Frank, Wilkinson Brimmer Katcher served as strategic communications adviser. Sidley Austin provided legal counsel to AIP, with Baker Botts serving as regulatory counsel.
Under the agreement, Avanos shareholders will receive $25 per share in cash. This purchase price represents a 72.1% premium over Avanos' closing stock price on the last trading day before the announcement and an 82.8% premium over the company's 30-day volume-weighted average share price. Avanos Medical's Board of Directors unanimously approved the transaction.
Alpharetta, Georgia-based Avanos Medical specializes in medical devices targeting chronic pain management without opioids, alongside clinical nutrition solutions including enteral feeding systems for patients unable to eat independently. AIP's investment thesis centers on Coolief, the company's flagship product that employs minimally invasive radiofrequency technology to interrupt pain signals by targeting specific nerves. This positioning within the non-opioid pain management segment reflects the broader healthcare industry shift away from opioid-based therapies. Avanos operates within a competitive landscape dominated by established medtech players such as Stryker, Medtronic, and Boston Scientific, which offer competing ablation-based solutions as part of their broader device portfolios.
The transaction is expected to close in the second half of 2026, subject to customary approvals and conditions including Avanos stockholder approval, expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, and other regulatory consents. Notably, the deal is not subject to a financing condition. Following closing, Avanos will become a private company and will delist from the New York Stock Exchange.
JP Morgan Securities served as lead financial adviser to Avanos, with UBS Investment Bank also acting as financial adviser. Alston & Bird provided legal counsel to Avanos, while Joele Frank, Wilkinson Brimmer Katcher served as strategic communications adviser. Sidley Austin provided legal counsel to AIP, with Baker Botts serving as regulatory counsel.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.